In the past week, CDT stock has gone up by 23.89%, with a monthly decline of -13.49% and a quarterly plunge of -34.69%. The volatility ratio for the week is 20.89%, and the volatility levels for the last 30 days are 15.73% for Conduit Pharmaceuticals Inc. The simple moving average for the past 20 days is 7.14% for CDT’s stock, with a -92.86% simple moving average for the past 200 days.
Is It Worth Investing in Conduit Pharmaceuticals Inc (NASDAQ: CDT) Right Now?
The 36-month beta value for CDT is also noteworthy at 2.19.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for CDT is 54.16M, and at present, short sellers hold a 6.59% of that float. The average trading volume of CDT on November 22, 2024 was 21.60M shares.
CDT) stock’s latest price update
Conduit Pharmaceuticals Inc (NASDAQ: CDT)’s stock price has gone decline by -1.95 in comparison to its previous close of 0.11, however, the company has experienced a 23.89% increase in its stock price over the last five trading days. globenewswire.com reported 2024-11-21 that NAPLES, Fla. and CAMBRIDGE, United Kingdom, Nov. 21, 2024 (GLOBE NEWSWIRE) — Conduit Pharmaceuticals Inc. (Nasdaq: CDT) (“Conduit Pharmaceuticals” or “Conduit” or the “Company”) today announced that the Japan Patent Office (JPO) has granted approval of a composition of matter patent application for the Company’s lead asset, AZD1656, a Glucokinase Activator targeting a wide range of autoimmune disorders.
CDT Trading at -3.19% from the 50-Day Moving Average
After a stumble in the market that brought CDT to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -98.65% of loss for the given period.
Volatility was left at 15.73%, however, over the last 30 days, the volatility rate increased by 20.89%, as shares sank -7.31% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -22.58% lower at present.
During the last 5 trading sessions, CDT rose by +21.66%, which changed the moving average for the period of 200-days by -96.79% in comparison to the 20-day moving average, which settled at $0.0987. In addition, Conduit Pharmaceuticals Inc saw -97.67% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at CDT starting from Nirland Ltd, who sale 1,500,000 shares at the price of $0.10 back on Oct 03 ’24. After this action, Nirland Ltd now owns 8,400,000 shares of Conduit Pharmaceuticals Inc, valued at $156,450 using the latest closing price.
Nirland Ltd, the 10% Owner of Conduit Pharmaceuticals Inc, sale 1,368,991 shares at $0.10 during a trade that took place back on Oct 04 ’24, which means that Nirland Ltd is holding 7,031,009 shares at $140,458 based on the most recent closing price.
Stock Fundamentals for CDT
Current profitability levels for the company are sitting at:
- -0.01 for the present operating margin
- 0.37 for the gross margin
The net margin for Conduit Pharmaceuticals Inc stands at 0.03. The total capital return value is set at 1.42. Equity return is now at value -89.65, with -181.68 for asset returns.
Based on Conduit Pharmaceuticals Inc (CDT), the company’s capital structure generated -0.36 points at debt to capital in total, while cash flow to debt ratio is standing at -4.43. The debt to equity ratio resting at -0.26. The interest coverage ratio of the stock is -14.58.
Currently, EBITDA for the company is -0.32 million with net debt to EBITDA at -0.21. When we switch over and look at the enterprise to sales, we see a ratio of 0.01. The receivables turnover for the company is 2445.42for trailing twelve months and the total asset turnover is 599.71. The liquidity ratio also appears to be rather interesting for investors as it stands at 0.12.
Conclusion
In summary, Conduit Pharmaceuticals Inc (CDT) has had a bad performance as of late. Analysts have mixed opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
